Benjamin F. Edwards & Company’s Adial Pharmaceuticals ADIL Stock Holding History

Benjamin F. Edwards & Company’s Portfolio ADIL Stock Details ADIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$0	Hold	2	–	–	﹤0.01%	2125
2024 Q1	$0	Hold	2	–	–	﹤0.01%	2109
2023 Q4	$0	Hold	2	–	–	﹤0.01%	2078
2023 Q3	$0	Hold	2	–	–	﹤0.01%	1741
2023 Q2	$0	Hold	2	–	–	﹤0.01%	1753
2023 Q1	$0	Hold	2	–	–	﹤0.01%	1772
2022 Q4	$0	Hold	2	–	–	﹤0.01%	1832
2022 Q3	$0	Hold	2	–	–	﹤0.01%	1809
2022 Q2	$1K	Hold	2	–	–	﹤0.01%	1726
2022 Q1	$2K	Hold	2	–	–	﹤0.01%	1640
2021 Q4	$3K	Hold	2	–	–	﹤0.01%	1582
2021 Q3	$4K	Buy	+2	New	+$4.19K	﹤0.01%	1546

Other funds holding ADIL

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

MCM

Manchester Capital Management Manchester, Vermont $768M AUM 29.32% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

1IA

1620 Investment Advisors Plymouth, Massachusetts $161M AUM 30.15% 1-Year Est. Return

RWM

Raffa Wealth Management Washington, District of Columbia $793M AUM 13.11% 1-Year Est. Return

Benjamin F. Edwards & Company's ADIL Position: Q2 2024 in Review

Benjamin F. Edwards & Company held its Adial Pharmaceuticals (ADIL) position steady in Q2 2024 at 2 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2125.

Benjamin F. Edwards & Company first reported a position in ADIL in Q3 2021 and has held it in 12 quarters since. The position peaked at $4K in Q3 2021. 15 funds tracked by Wall St. Rank hold ADIL as of Q2 2024.

Benjamin F. Edwards & Company held 2 shares of Adial Pharmaceuticals worth $0 as of Q2 2024.
Benjamin F. Edwards & Company left its Adial Pharmaceuticals share count unchanged in Q2 2024.
Adial Pharmaceuticals made up ﹤0.01% of Benjamin F. Edwards & Company's portfolio in Q2 2024, its #2125 holding.
Benjamin F. Edwards & Company first reported a position in Adial Pharmaceuticals in Q3 2021 and has held it in 12 quarters since.
Benjamin F. Edwards & Company's Adial Pharmaceuticals position peaked at $4K in Q3 2021.
15 funds tracked by Wall St. Rank held Adial Pharmaceuticals as of Q2 2024.

Based on Benjamin F. Edwards & Company's 13F filing for Q2 2024, filed 12 Aug 2024.